Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

JAZZ

Jazz Pharmaceuticals plc

May 03 • 04:00PM ET

110.01

Dollar change +0.72
Percentage change 0.66	%

Healthcare • Biotechnology • Ireland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IJH VB COWZ VBR VXF VHT IJJ IWR FXH

Index	-	P/E	23.93	EPS (ttm)	4.60	Insider Own	3.34%	Shs Outstand	62.26M	Perf Week	0.50%
Market Cap	6.94B	Forward P/E	5.30	EPS next Y	20.74	Insider Trans	0.36%	Shs Float	60.93M	Perf Month	-4.51%
Income	330.79M	PEG	5.32	EPS next Q	4.74	Inst Own	91.48%	Short Float	6.08%	Perf Quarter	-10.49%
Sales	3.84B	P/S	1.80	EPS this Y	1.37%	Inst Trans	-0.76%	Short Ratio	5.95	Perf Half Y	-13.61%
Book/sh	58.65	P/B	1.88	EPS next Y	11.86%	ROA	2.96%	Short Interest	3.70M	Perf Year	-19.48%
Cash/sh	28.84	P/C	3.81	EPS next 5Y	4.50%	ROE	9.41%	52W Range	103.01 - 146.70	Perf YTD	-10.56%
Dividend Est.	-	P/FCF	6.86	EPS past 5Y	-3.53%	ROI	3.73%	52W High	-25.01%	Beta	0.64
Dividend TTM	-	Quick Ratio	1.78	Sales past 5Y	15.52%	Gross Margin	73.55%	52W Low	6.80%	ATR (14)	3.05
Dividend Ex-Date	-	Current Ratio	2.15	EPS Y/Y TTM	310.66%	Oper. Margin	15.83%	RSI (14)	42.69	Volatility	3.82% 2.53%
Employees	2800	Debt/Eq	1.57	Sales Y/Y TTM	2.81%	Profit Margin	8.61%	Recom	1.55	Target Price	180.78
Option/Short	Yes / Yes	LT Debt/Eq	1.40	EPS Q/Q	-124.85%	Payout	0.00%	Rel Volume	1.11	Prev Close	109.29
Sales Surprise	-5.45%	EPS Surprise	-35.87%	Sales Q/Q	1.03%	Earnings	May 01 AMC	Avg Volume	622.41K	Price	110.01
SMA20	-0.67%	SMA50	-6.01%	SMA200	-12.11%	Trades		Volume	693,768	Change	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$195 → $207
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight	$150 → $175
Jan-29-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-16-20	Initiated	UBS	Buy	$174
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$185 → $195
Oct-09-20	Reiterated	H.C. Wainwright	Buy	$175 → $185
Sep-14-20	Resumed	JP Morgan	Overweight	$175

Show Previous Ratings

May-03-24 12:41PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
11:49AM	UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating (MT Newswires)
May-02-24 11:26AM	Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates (Zacks)
03:53AM	Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook (MT Newswires)
May-01-24 08:56PM	JAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00PM	Loading…
07:00PM	Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:24PM	Jazz: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference (PR Newswire)
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance (PR Newswire)
Apr-30-24 09:50AM	Jazz Pharmaceuticals Focuses on Taking Actions To Positively Impact the Planet This Earth Month (ACCESSWIRE)
Apr-24-24 04:05PM	Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 (PR Newswire)
10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
05:21AM	3 No-Brainer Stocks to Buy With $300 Right Now (Motley Fool)
Apr-23-24 11:15AM	Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community (ACCESSWIRE)
Apr-17-24 04:15PM	Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 (PR Newswire)
07:45AM	Loading…
Apr-10-24 07:45AM	Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting (PR Newswire)
Apr-04-24 09:15AM	Following the Money Trail: Where are Hedge Funds Investing? (Insider Monkey)
Apr-02-24 07:30AM	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer (PR Newswire)
Mar-29-24 11:30AM	Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report? (Zacks)
Mar-28-24 10:15AM	Cancer and the Combination Approach (ACCESSWIRE)
Mar-20-24 10:15AM	Jazz Pharmaceuticals Celebrates International Womens Day (ACCESSWIRE)
Mar-18-24 03:28PM	20 States with the Cheapest Weed in America (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 12:00PM	Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month (ACCESSWIRE)
10:00AM	Unlocking Jazz Pharmaceuticals' Potential: A Roadmap for Growth (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 05:34PM	11 Stocks Insiders are Buying Now (Insider Monkey)
04:15PM	Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 (PR Newswire)
Mar-09-24 11:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Mar-07-24 01:51PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
01:10PM	Loading…
01:10PM	Q4 2023 Zymeworks Inc Earnings Call (Thomson Reuters StreetEvents)
10:08AM	10 Mid-Cap Stocks with Insider Purchases (Insider Monkey)
Feb-29-24 10:45AM	Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates (Zacks) -8.33%
10:35AM	Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 06:30PM	Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings (Zacks)
05:20PM	Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates (Zacks)
04:33PM	Jazz Pharmaceuticals PLC (JAZZ) Reports Strong Revenue Growth and Robust Pipeline Progress (GuruFocus.com)
04:29PM	Jazz: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance (PR Newswire)
Feb-27-24 10:15PM	Q4 2023 Ligand Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:45AM	Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors (PR Newswire)
Feb-24-24 05:06AM	4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Feb-23-24 09:15AM	Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-21-24 08:50AM	Jazz Pharmaceuticals Names Eli Lillys Philip Johnson as Next CFO (The Wall Street Journal)
07:45AM	Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer (PR Newswire)
Feb-20-24 05:00PM	3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
04:15PM	Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-14-24 04:15PM	Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024 (PR Newswire)
Feb-13-24 10:15AM	Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals (ACCESSWIRE)
Feb-09-24 09:15AM	How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1 (ACCESSWIRE)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
02:00AM	Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program (PR Newswire)
Feb-03-24 05:06AM	4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Jan-31-24 03:33PM	25 Most Cannabis Consuming-Countries in the World (Insider Monkey)
12:03PM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024 (InvestorPlace)
Jan-22-24 05:16AM	2 Incredible Growth Stocks That Are Screaming Buys for 2024 (Motley Fool)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-13-24 05:06AM	4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Dec-28-23 10:06PM	7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World (InvestorPlace)
Dec-22-23 12:07PM	Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals (Zacks)
11:16AM	Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study (Benzinga)
Dec-21-23 04:17PM	UPDATE 1-Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial (Reuters)
04:09PM	Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial (Reuters)
04:05PM	Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder (PR Newswire)
Dec-20-23 04:15PM	Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
05:21AM	3 No-Brainer Stocks to Buy With $500 Right Now (Motley Fool)
Dec-08-23 01:20PM	Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer (PR Newswire)
11:30AM	Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report? (Zacks)
09:15AM	Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global Communities (ACCESSWIRE)
Dec-01-23 09:02AM	Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting (PR Newswire)
Nov-30-23 07:45AM	Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings (PR Newswire)
Nov-29-23 11:15AM	Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Using Natural Resources Responsibly (ACCESSWIRE)
Nov-28-23 08:48AM	3 Top-Rated Biotech Stocks That Analysts Are Loving Now (InvestorPlace)
Nov-27-23 09:49AM	5 Best Upside Stocks To Buy Now (Insider Monkey)
Nov-15-23 05:21AM	3 No-Brainer Stocks to Buy With $200 Right Now (Motley Fool)
Nov-14-23 12:50PM	12 Best Value Stocks To Buy Heading Into 2024 (Picked By Seth Klarman) (Insider Monkey)
02:00AM	Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders (Business Wire)
Nov-09-23 05:07PM	Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.14%
Nov-08-23 07:00PM	Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics (Zacks)
05:52PM	Jazz Pharmaceuticals PLC (JAZZ) Reports Solid Q3 2023 Results and Raises Revenue Guidance (GuruFocus.com)
04:42PM	Jazz: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
Nov-07-23 12:33PM	Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key Metrics (Zacks)
07:45AM	Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers (PR Newswire)
Nov-01-23 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences (PR Newswire)
10:01AM	Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-31-23 05:42PM	10 Stocks That Will Skyrocket (Insider Monkey)
Oct-30-23 04:05PM	11 Best Long-Term Stocks To Buy For High Returns (Insider Monkey)
Oct-26-23 11:40AM	JAZZ vs. ZTS: Which Stock Is the Better Value Option? (Zacks)
Oct-25-23 04:15PM	Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023 (PR Newswire)
08:34AM	Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength? (Zacks)
08:30AM	Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 (PR Newswire)
Oct-23-23 07:45AM	Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023 (PR Newswire)
Oct-21-23 06:38AM	Wyndham rebuffs Choice Hotels; Southwestern surges on M&A talk: 4 big deal reports (Investing.com)
Oct-20-23 10:30AM	Jazz Pharmaceuticals Said to Explore Options Including Sale (Bloomberg)
Oct-18-23 07:55AM	5 Value Stocks With High Earnings Yield to Boost Your Portfolio (Zacks)
07:45AM	Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023 (PR Newswire)
Oct-17-23 09:55AM	Does Jazz (JAZZ) Have the Potential to Rally 47.29% as Wall Street Analysts Expect? (Zacks)
04:21AM	Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-16-23 07:45AM	Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023 (PR Newswire) +5.33%

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carr Patricia	SVP, Chief Accounting Officer	Mar 07 '24	Sale	116.98	1,768	206,821	6,596	Mar 08 06:07 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 06 '24	Sale	119.64	1,936	231,628	8,364	Mar 08 06:07 PM
Johnson Philip L	EVP & Chief Financial Officer	Mar 01 '24	Buy	119.65	12,000	1,435,800	27,932	Mar 05 07:28 PM
Cook Jennifer E.	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888	Dec 06 04:31 PM
Smith Mark Douglas	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888	Dec 06 04:39 PM
Patil Neena M	EVP & Chief Legal Officer	Sep 01 '23	Sale	144.25	1,500	216,375	29,186	Sep 06 05:09 PM
Carr Patricia	SVP, Chief Accounting Officer	Aug 29 '23	Sale	143.47	142	20,373	5,986	Aug 31 06:44 PM
Patil Neena M	EVP & Chief Legal Officer	Aug 15 '23	Sale	139.59	750	104,695	30,686	Aug 17 05:21 PM
McSharry Heather Ann	Director	Aug 14 '23	Sale	138.16	1,344	185,685	16,778	Aug 15 05:52 PM
Sohn Catherine A.	Director	Aug 14 '23	Sale	138.16	1,241	171,455	14,868	Aug 15 06:02 PM
ENRIGHT PATRICK G	Director	Aug 14 '23	Sale	138.16	1,241	171,455	20,946	Aug 15 05:45 PM
O'Keefe Kenneth W	Director	Aug 14 '23	Sale	138.16	1,241	171,455	24,723	Aug 15 07:49 PM
Winningham Rick E	Director	Aug 14 '23	Sale	138.16	1,241	171,455	10,444	Aug 15 06:08 PM
Gray Peter	Director	Aug 14 '23	Sale	138.16	1,241	171,455	16,068	Aug 15 05:47 PM
Cook Jennifer E.	Director	Aug 14 '23	Sale	138.16	1,241	171,454	7,305	Aug 15 05:44 PM
RIEDEL NORBERT G	Director	Aug 14 '23	Sale	138.16	1,241	171,454	13,705	Aug 15 05:58 PM
ORiordan Anne	Director	Aug 14 '23	Sale	138.16	1,241	171,454	12,551	Aug 15 07:51 PM
Smith Mark Douglas	Director	Aug 14 '23	Sale	138.16	1,241	171,454	7,305	Aug 15 06:00 PM
Carr Patricia	SVP, Chief Accounting Officer	Aug 14 '23	Sale	138.16	158	21,829	6,128	Aug 15 05:43 PM
Mulligan Seamus	Director	Jun 08 '23	Option Exercise	81.76	4,500	367,920	1,169,300	Jun 12 04:47 PM
Carr Patricia	SVP, Chief Accounting Officer	Jun 07 '23	Sale	127.92	126	16,117	6,286	Jun 09 04:55 PM
Patil Neena M	EVP & Chief Legal Officer	Jun 01 '23	Sale	127.98	1,600	204,763	32,826	Jun 05 08:24 PM
GALA RENEE D	EVP & Chief Financial Officer	May 18 '23	Sale	131.75	6,000	790,474	35,978	May 19 08:45 PM

Open in Screener

VERA

Vera Therapeutics Inc

May 03 • 04:00PM ET

43.44

Dollar change -0.06
Percentage change -0.14	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

VERA Vera Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IBB SCHA DWAS IWN IWO VTWO LABU

Index	RUT	P/E	-	EPS (ttm)	-2.28	Insider Own	26.56%	Shs Outstand	44.45M	Perf Week	9.56%
Market Cap	2.33B	Forward P/E	-	EPS next Y	-2.33	Insider Trans	-11.47%	Shs Float	39.44M	Perf Month	16.12%
Income	-95.99M	PEG	-	EPS next Q	-0.53	Inst Own	63.58%	Short Float	16.01%	Perf Quarter	10.96%
Sales	0.00M	P/S	-	EPS this Y	3.08%	Inst Trans	1.76%	Short Ratio	5.87	Perf Half Y	297.44%
Book/sh	2.29	P/B	18.99	EPS next Y	-7.07%	ROA	-62.54%	Short Interest	6.31M	Perf Year	514.43%
Cash/sh	2.99	P/C	14.52	EPS next 5Y	-	ROE	-107.50%	52W Range	6.70 - 50.78	Perf YTD	182.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.22%	ROI	-62.76%	52W High	-14.45%	Beta	1.11
Dividend TTM	-	Quick Ratio	7.42	Sales past 5Y	0.00%	Gross Margin	-	52W Low	548.36%	ATR (14)	3.01
Dividend Ex-Date	-	Current Ratio	7.42	EPS Y/Y TTM	31.36%	Oper. Margin	0.00%	RSI (14)	55.25	Volatility	6.67% 8.05%
Employees	51	Debt/Eq	0.53	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	59.22
Option/Short	Yes / Yes	LT Debt/Eq	0.50	EPS Q/Q	50.54%	Payout	-	Rel Volume	0.54	Prev Close	43.50
Sales Surprise	-	EPS Surprise	-8.12%	Sales Q/Q	-	Earnings	Mar 20 BMO	Avg Volume	1.08M	Price	43.44
SMA20	5.60%	SMA50	1.29%	SMA200	78.88%	Trades		Volume	582,113	Change	-0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Apr-23-24 05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 07:01PM	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... (GuruFocus.com)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
08:00AM	Loading…
Apr-02-24 08:00AM	Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress (GlobeNewswire)
Mar-20-24 12:52PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 04:20PM	Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-02-24 12:40PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Ray Dalio, Ken Griffin, NWQ Capital Management, Man Group, Cleveland-Cliffs Inc (CLF), Vera Therapeutics, Inc. (VERA), and More (Insider Monkey)
08:00AM	Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-01-24 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Jan-29-24 11:50PM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) +11.46%
06:15AM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Jan-25-24 06:30AM	Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy (GlobeNewswire) +48.71%
06:44PM	Loading…
Jan-12-24 06:44PM	Why Vera Therapeutics Stock Soared by 22% This Week (Motley Fool)
Jan-08-24 08:01AM	Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer (GlobeNewswire) +16.74%
08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 (GlobeNewswire)
Dec-27-23 08:00AM	Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-23 10:15AM	This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street (Motley Fool) +8.70%
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Vera Therapeutics Inc (GuruFocus.com) +6.74%
09:55AM	Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade (Zacks)
Nov-09-23 09:29AM	Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business Updates (GuruFocus.com)
08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-23 10:00AM	Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-30-23 08:00AM	Vera Therapeutics Scheduled to Present at November Investor Conferences (GlobeNewswire) +8.32%
Oct-18-23 09:35AM	Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks) -5.09%
Oct-17-23 09:35AM	Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks)
Oct-16-23 09:35AM	Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround (Zacks)
Oct-13-23 10:22AM	Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
04:02PM	Loading…
Sep-26-23 04:02PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +11.32%
Aug-31-23 08:00AM	Vera Therapeutics Scheduled to Present at September Investor Conferences (GlobeNewswire) -5.70%
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly)
Aug-15-23 04:03PM	What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock (Zacks)
Aug-10-23 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results (GlobeNewswire) +6.22%
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-24-23 09:01AM	Positive Signs As Multiple Insiders Buy Vera Therapeutics Stock (Simply Wall St.) -6.82%
Jul-07-23 06:35PM	Masimo and Vera Therapeutics Stock See Action From Activist Investors (Barrons.com) +5.20%
Jun-27-23 08:05AM	Vera Therapeutics Likely Needs Time to Digest Its Recent Dramatic Gains (TheStreet.com)
Jun-20-23 07:04PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +16.94%
09:33AM	2 Surging Healthcare Stocks With More Fuel in the Tank (Motley Fool)
Jun-17-23 10:10AM	Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress (GlobeNewswire)
Jun-15-23 04:44PM	Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN (GlobeNewswire)
Jun-12-23 12:05PM	Why Shares of Vera Therapeutics Are Soaring Monday (Motley Fool) +15.83%
Jun-11-23 01:08PM	7 Stocks That Wall Street Analysts Are Loving in June (InvestorPlace)
Jun-08-23 08:00AM	Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-07-23 08:00AM	Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire)
May-11-23 08:36AM	Should You Buy Vera Therapeutics (VERA) Ahead of Earnings? (Zacks)
07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results (GlobeNewswire)
May-04-23 08:00AM	Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
Mar-28-23 07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 04:05PM	Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-14-23 07:48AM	Chief Financial Officer Sean Grant Just Bought 207% More Shares In Vera Therapeutics, Inc. (NASDAQ:VERA) (Simply Wall St.)
Feb-09-23 06:51AM	Daily Vickers Top Buyers & Sellers for 02/09/2023 (Argus Research)
05:54AM	With 35% stake, Vera Therapeutics, Inc. (NASDAQ:VERA) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-06-23 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Feb-01-23 09:52PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
04:01PM	Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock (GlobeNewswire)
Jan-30-23 07:35AM	Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs (Benzinga) -6.06%
06:00AM	Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria (GlobeNewswire)
Jan-25-23 08:00AM	Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN) (GlobeNewswire)
Jan-22-23 07:39AM	Why Vera Therapeutics Stock Bolted Higher This Week (Motley Fool)
Jan-06-23 05:02AM	The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax (Zacks)
Jan-04-23 04:07PM	Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update And Chinook Popped (Investor's Business Daily) -64.70%
12:20PM	VERA Dips Despite Positive Data From IgA Nephropathy Study (Zacks)
10:22AM	These 2 Nasdaq Biotechs Are Making Big Moves Wednesday (Motley Fool)
06:52AM	Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study (Benzinga)
Jan-03-23 04:01PM	Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (GlobeNewswire) -5.43%
Dec-20-22 04:05PM	Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-22 07:38AM	One Vera Therapeutics, Inc. (NASDAQ:VERA) insider upped their stake by 329% in the previous year (Simply Wall St.)
Nov-22-22 07:30AM	Vera Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-17-22 07:30AM	Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP (GlobeNewswire)
Nov-09-22 07:30AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.00%
Nov-05-22 04:50PM	Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 07:30AM	Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Sep-15-22 09:55AM	Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a Bet (Zacks)
Sep-07-22 07:30AM	Vera Therapeutics to Present at Upcoming Conferences in September 2022 (GlobeNewswire) +5.93%
Aug-29-22 09:55AM	Wall Street Analysts See a 76% Upside in Vera Therapeutics, Inc. (VERA): Can the Stock Really Move This High? (Zacks) +11.10%
Aug-12-22 09:55AM	Can Vera Therapeutics, Inc. (VERA) Climb 79% to Reach the Level Wall Street Analysts Expect? (Zacks) +5.17%
Aug-10-22 07:30AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +9.03%
Aug-04-22 07:30AM	Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-06-22 07:30AM	Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (GlobeNewswire)
Jun-18-22 08:20AM	Insider Buying: The Vera Therapeutics, Inc. (NASDAQ:VERA) Chief Financial Officer Just Bought 329% More Shares (Simply Wall St.)
Jun-04-22 02:30PM	Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients (GlobeNewswire)
Jun-02-22 07:30AM	Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-20-22 04:05PM	Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress (GlobeNewswire)
May-16-22 07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 04:05PM	Vera Therapeutics to Present at Upcoming Conferences in May 2022 (GlobeNewswire)
May-03-22 04:33PM	Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus (GlobeNewswire) -5.66%
May-02-22 07:06PM	Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022 (GlobeNewswire)
Apr-12-22 07:30AM	Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors (GlobeNewswire)
Mar-24-22 06:30AM	Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-21-22 07:30AM	Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher (GlobeNewswire) -7.30%
Mar-17-22 07:30AM	Vera Therapeutics to Host Business Update Call (GlobeNewswire)
Mar-01-22 07:30AM	Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-22-22 05:29AM	We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-14-22 04:01PM	Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-22 08:46AM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) -6.56%
Feb-07-22 05:24PM	Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock (GlobeNewswire) +7.72%
Jan-18-22 07:30AM	Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Apr 10 '24	Sale	40.00	5,714	228,560	53,171	Apr 12 04:02 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Option Exercise	14.87	99,828	1,484,442	166,165	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.61	99,828	3,954,516	66,337	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.42	18,649	735,205	0	Apr 05 09:32 PM
Katabi Maha	Director	Mar 25 '24	Sale	40.50	340,000	13,770,000	2,793,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 22 '24	Sale	40.51	413,450	16,748,860	3,133,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 21 '24	Sale	44.20	81,009	3,580,723	3,547,437	Mar 25 09:46 PM
Katabi Maha	Director	Jan 30 '24	Buy	31.00	161,290	4,999,990	3,628,446	Feb 01 05:58 PM
COMMODORE CAPITAL LP	10% Owner	Jan 10 '24	Sale	18.00	1,050,000	18,900,000	4,400,000	Jan 12 09:55 PM
Fordyce Marshall	President and CEO	Dec 29 '23	Option Exercise	2.87	13,516	38,854	256,877	Jan 03 04:15 PM
Fordyce Marshall	President and CEO	Aug 21 '23	Sale	16.66	5,210	86,779	243,361	Aug 23 05:56 PM
Curley Joanne	Chief Development Officer	Aug 21 '23	Sale	16.66	1,490	24,817	26,962	Aug 23 05:57 PM
Lin Celia	Chief Medical Officer	Aug 21 '23	Sale	16.65	1,490	24,816	11,010	Aug 23 05:59 PM
Young Joseph R	SVP, Finance, Chief Acct Offcr	Jul 05 '23	Option Exercise	3.94	10,000	39,396	32,679	Jul 06 04:05 PM
Grant Sean	Chief Financial Officer	Jun 23 '23	Buy	16.60	5,000	83,000	5,992	Jun 23 04:05 PM
COMMODORE CAPITAL LP	10% Owner	Jun 20 '23	Buy	15.17	448,217	6,799,004	5,450,000	Jun 22 04:10 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

JAZZ

Jazz Pharmaceuticals plc

VERA

Vera Therapeutics Inc

Upgrade your FINVIZ experience